HULL, England, May 25, 2011 /PRNewswire/ --
- With Photo
The Advanced Wound Management division of Smith & Nephew, (LSE: SN; NYSE: SNN) today announced the CE Mark approval for PICO(TM), an effective, single-use, Negative Pressure Wound Therapy (NPWT) system for acute and chronic wounds, high-risk surgical incisions and skin grafts. PICO allows effective fluid management directly through the dressing, eliminating canisters and expanding negative pressure to a wider number of patients. PICO is now available throughout the European Union (EU) and was officially unveiled at the European Wound Management Association (EWMA) conference taking place in Brussels, Belgium [25-27 May].
The PICO system contains a disposable, one-button pump, coupled with an advanced dressing which negates the need for a bulky canister, simplifying NPWT. The pump is pocket-sized for the utmost patient privacy and the innovative dressing can be worn up to seven days.
"A system like PICO that combines the clinical effectiveness of NPWT with the known benefits of advanced wound care dressings is an ideal solution for appropriate patients, especially those at high risk in the critical days following surgery," said Professor Donald Hudson, Head of the Department of Plastic Surgery at the University of Cape Town, South Africa and Groote Schuur Hospital. "PICO opens up some very interesting possibilities in treating many kinds of small to medium sized wounds in both hospital and outpatient settings."
Preclinical studies show that PICO delivered pressure to the wound bed, tissue contraction and blood flow in a virtually identical fashion to standard NPWT. In vitro tests also show that PICO was able to deliver negative pressure and remove exudate at clinically relevant levels without the need for a canister. This effective and simplified NPWT technology makes PICO a practical solution that is readily available with minimal administration and training, allowing clinicians to make the most of their time and resources.
"At Smith & Nephew we believe it's our responsibility to achieve both superior patient outcomes as well as conserve resources for healthcare systems," said Roger Teasdale, President of Smith & Nephew Advanced Wound Management. "As a leader in wound care, PICO demonstrates our pledge to providing innovative solutions and reinforces our commitment to reducing the human and economic cost of wounds."
For more information about PICO, please visit www.mypico.co
About Smith & Nephew
Smith & Nephew is a global medical technology business with global leadership positions in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy, including Sports Medicine; and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company has distribution channels, purchasing agents and buying entities in over 90 countries worldwide. Annual sales in 2010 were nearly $4.0 billion.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
(TM) Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Note to Editors:
A picture accompanying this release is available through the PA Photowire. It can be downloaded from http://www.pa-mediapoint.press.net or viewed at http://www.mediapoint.press.net or http://www.prnewswire.co.uk.
SOURCE Smith & Nephew